Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauren A Byers

Showing results (1-10 of 133) with videos related to

Pageof 14
Sort By:
Clinical Lung Cancer|March 27, 2007
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancerLauren A Byers, John V Heymach
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?Carl M Gay, Lauren A Byers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--responseRobert J G Cardnell, Lauren A Byers
Molecular Cancer Research : MCR|January 21, 2014
Smoking, p53 mutation, and lung cancerDon L Gibbons, Lauren A Byers, Jonathan M Kurie
Cancer|March 5, 2025
Top advances of the year: Small cell lung cancerMisty D Shields, Anne C Chiang, Lauren A Byers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2018
Reply to F. LiangM Catherine Pietanza, Lixia Diao, Jing Wang, et al.
Nature Cancer|June 5, 2025
The current and emerging immunotherapy paradigm in small-cell lung cancerKang Qin, Carl M Gay, Lauren A Byers, et al.
British Journal of Cancer|December 17, 2020
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage responseNiamh Coleman, Bingnan Zhang, Lauren A Byers, et al.
Cancer|January 9, 2019
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint eraCarminia M Della Corte, Carl M Gay, Lauren A Byers
Molecular Cell|January 20, 2023
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor controlKyle Concannon, Benjamin B Morris, Carl M Gay, et al.
Pageof 14

Showing results (1-10 of 133) with videos related to

Sort By:
Pageof 14
Clinical Lung Cancer|March 27, 2007
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancerLauren A Byers, John V Heymach
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2019
PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?Carl M Gay, Lauren A Byers
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer--responseRobert J G Cardnell, Lauren A Byers
Molecular Cancer Research : MCR|January 21, 2014
Smoking, p53 mutation, and lung cancerDon L Gibbons, Lauren A Byers, Jonathan M Kurie
Cancer|March 5, 2025
Top advances of the year: Small cell lung cancerMisty D Shields, Anne C Chiang, Lauren A Byers
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2018
Reply to F. LiangM Catherine Pietanza, Lixia Diao, Jing Wang, et al.
Nature Cancer|June 5, 2025
The current and emerging immunotherapy paradigm in small-cell lung cancerKang Qin, Carl M Gay, Lauren A Byers, et al.
British Journal of Cancer|December 17, 2020
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage responseNiamh Coleman, Bingnan Zhang, Lauren A Byers, et al.
Cancer|January 9, 2019
Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint eraCarminia M Della Corte, Carl M Gay, Lauren A Byers
Molecular Cell|January 20, 2023
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor controlKyle Concannon, Benjamin B Morris, Carl M Gay, et al.
Pageof 14